UI Hospitals and Clinics

Clinical Trial Details

Short Title
Study for Safety of the Drug Ruxolitnib
Official Title

Study for Safety of the Drug Ruxolitnib


An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis who have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L

Participants in this study have been diagnosed with Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis or Post Polycythemia Vera Myelofibrosis and have low platelet counts as a consequence of their disease. The study is being done to find out if the drug ruxolitinib is safe and has beneficial effects in people with this disease. There will be approximately 150 subjects across the United States including the University of Iowa. 

Start Date
August 17, 2011
End Date
August 17, 2021
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Thomas Carter, MD, PhD
Contact Info

Karen Parrott, 319-353-6347

Department or Field of Study
cancer ; carter ; IRB#201105687 ; phase 2 ; phase II ; Post Polycythemia Vera Myelofibrosis ; Post-Essential Thrombocythemia Myelofibrosis ; Primary Myelofibrosis ; ruxolitinib ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.